Mersana Misses Fiscal Q2 Revenue Target
Mersana Therapeutics (NASDAQ:MRSN), a clinical-stage biotech specializing in antibody-drug conjugates (ADCs) for cancer, reported its second quarter results on August 13, 2025. The company’s update featured continued clinical development progress and the start of new expansion cohorts in its lead programs. However, the numbers fell well below Wall Street expectations, with a net loss of $4.87 per share (GAAP) and revenue (GAAP) of $3.1 million, both missing their respective estimates by a wide margin. The company also highlighted ongoing cost management, though cash reserves fell from prior levels as it continues to fund research and restructuring. The quarter demonstrated some stabilization after recent restructuring but also underlined continued pressure on revenue, earnings, and near-term liquidity.
Source: Analyst estimates for the quarter provided by FactSet.
Mersana Therapeutics develops antibody-drug conjugates, or ADCs. These are targeted cancer therapies that deliver powerful drugs directly into cancer cells, aiming to improve effectiveness and limit side effects. The company’s proprietary ADC technology platforms are Dolasynthen, which creates cytotoxic ADCs, and Immunosynthen, focused on immune-stimulating ADCs that activate the body's own anti-tumor defenses.
Source Fool.com
